| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/27/2000 | CA2360908A1 Bis-terpyridine-platinum(ii) complexes |
| 07/27/2000 | CA2360787A1 Phosphinic pseudopeptides inhibitors of matrix metalloproteases |
| 07/27/2000 | CA2360730A1 Human liver progenitors |
| 07/27/2000 | CA2360062A1 Baff, inhibitors thereof and their use in the modulation of b-cell response |
| 07/27/2000 | CA2359680A1 Kinase inhibitors |
| 07/27/2000 | CA2359633A1 Homing pro-apoptotic conjugates and methods of using same |
| 07/27/2000 | CA2359561A1 Proteasome inhibitors |
| 07/27/2000 | CA2359114A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | CA2359113A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | CA2359112A1 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | CA2359105A1 New morpholinobenzamide salts |
| 07/27/2000 | CA2358989A1 Method for improved radiation therapy |
| 07/27/2000 | CA2358971A1 Identifying, monitoring, and treating women for breast precancer or cancer |
| 07/27/2000 | CA2358963A1 Cancer-associated proteins |
| 07/27/2000 | CA2358899A1 Polypeptide |
| 07/27/2000 | CA2358584A1 Method of enhancing needleless transdermal powdered drug delivery |
| 07/27/2000 | CA2358497A1 Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery |
| 07/27/2000 | CA2358093A1 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/27/2000 | CA2356349A1 Novel angiogenesis inhibitors |
| 07/27/2000 | CA2354375A1 Compositions and methods for the diagnosis and treatment of tumor |
| 07/26/2000 | EP1022277A1 New taxane derivatives |
| 07/26/2000 | EP1021564A1 Process for detecting, extracting or removing human or mammalian cells with a disturbed cellular cycle regulation or unlimited proliferation or tumour-forming ability |
| 07/26/2000 | EP1021549A2 SENSE mRNA THERAPY |
| 07/26/2000 | EP1021546A1 Neutral sphingomyelinase |
| 07/26/2000 | EP1021540A1 Human progesterone receptor complex p23-like protein |
| 07/26/2000 | EP1021536A2 Mammalian genes involved in viral infection and tumor suppression |
| 07/26/2000 | EP1021464A1 Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle |
| 07/26/2000 | EP1021448A1 TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS |
| 07/26/2000 | EP1021438A1 Trioxane dimer compounds having antiproliferative and antitumor activities |
| 07/26/2000 | EP1021437A1 Arylsulfonylimidazolone derivatives as an antitumor agent |
| 07/26/2000 | EP1021423A1 MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF$g(a) SECRETION |
| 07/26/2000 | EP1021413A1 The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 07/26/2000 | EP1021407A1 Synthesis of clasto-lactacystin beta-lactone and analogs thereof |
| 07/26/2000 | EP1021202A1 Immunogenic peptides from the hpv e7 protein |
| 07/26/2000 | EP1021201A1 Use of growth differenciation factor-9 (gdf-9) as a contraceptive |
| 07/26/2000 | EP1021197A1 Implants comprising combinations of allogeneic cells for use in cancer treatment |
| 07/26/2000 | EP1021196A2 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
| 07/26/2000 | EP1021193A1 THERAPEUTICALLY EFFECTIVE 1$g(a), 25-DIHYDROXYVITAMIN D 3? ANALOGS |
| 07/26/2000 | EP1021188A1 Inhibitors of prenyl-protein transferase |
| 07/26/2000 | EP1021186A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha |
| 07/26/2000 | EP1021182A1 Indeno[1,2-c] pyrazole derivatives for inhibiting tyrosine kinase activity |
| 07/26/2000 | EP1021178A1 Selenophene anti-tumor agents |
| 07/26/2000 | EP0769054B1 Immunomodulators |
| 07/26/2000 | EP0759775B1 Ifn-beta liquid formulations |
| 07/26/2000 | EP0643583B1 Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy |
| 07/26/2000 | CN1261373A Compositions and methods for activating genes of interest |
| 07/26/2000 | CN1261372A Natural antitumor or antiviral substances and use of the same |
| 07/26/2000 | CN1261370A Method of producing tiazofurin and other C-nucleosides |
| 07/26/2000 | CN1261358A Angiogenesis inhiting 5-substituted-1,2,4-thiadiazolyl derivatives |
| 07/26/2000 | CN1261354A Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases |
| 07/26/2000 | CN1261353A Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases |
| 07/26/2000 | CN1261352A New 'beta'-amino and 'beta'-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor an tagonists |
| 07/26/2000 | CN1261349A Chalcones having antiproliferactive activity |
| 07/26/2000 | CN1261275A Method and compositions for administering taxanes orally to human patients |
| 07/26/2000 | CN1261274A Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them. |
| 07/26/2000 | CN1261254A Nucleophile substituted ecteinascidins and N-oxide ecteinsacidins |
| 07/26/2000 | CN1261072A 7-halogenated and 7 beta, 8 beta-methylene-taxinol, its usage against cancers and medicinal compositions containing it |
| 07/26/2000 | CN1260998A Recombination adenovirus and its application in tumor treatment |
| 07/26/2000 | CN1260996A Compound injection for eliminating cancer |
| 07/26/2000 | CN1054856C New 19-nor steroids having phenoxyalkylsulphonemide or phenoxyalkylsulphonylurea chain in position llbeta, preparation process and intermediates, use as medicaments and pharmaceutical |
| 07/26/2000 | CN1054758C Medicine bar for fumigation |
| 07/26/2000 | CN1054753C Tianling kangfu pill for recovery |
| 07/26/2000 | CN1054747C Anti-cancer capsule |
| 07/25/2000 | US6093838 Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 07/25/2000 | US6093729 Substituted bicyclic heteroaroylguanidines, a process for their preparation, their use as a medicament or a diagnostic agent, and a medicament containing them |
| 07/25/2000 | US6093728 Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds |
| 07/25/2000 | US6093722 Administering an anticancer drug n-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a testosterone 5-alpha reductase enzyme inhibitor |
| 07/25/2000 | US6093721 Amidino-camptothecin derivatives |
| 07/25/2000 | US6093716 Substituted 2-pyrimidineamines and processes for their preparation |
| 07/25/2000 | US6093710 Benzothiophene derivatives, their preparation and use as urokinase inhibitors |
| 07/25/2000 | US6093707 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 07/25/2000 | US6093704 Use of dopamine receptor antagonists in palliative tumor therapy |
| 07/25/2000 | US6093694 Antitumor active substances |
| 07/25/2000 | US6093561 Human lysophospholipase |
| 07/25/2000 | US6093540 Method for diagnosing a disorder characterized by expression of a BAGE tumor rejection antigen precursor |
| 07/25/2000 | US6093399 Specific blood coagulation exemplified by in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody |
| 07/25/2000 | US6093382 Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| 07/25/2000 | CA2109727C Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
| 07/25/2000 | CA2049325C Peptide, immunogenic composition and vaccine or medicinal preparation; a method immunising a mammal against lhrh, and a method of improving the meat quality of pigs |
| 07/25/2000 | CA2031890C N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives |
| 07/25/2000 | CA2015377C Autoantibodies which enhance the rate of a chemical reaction |
| 07/25/2000 | CA2010256C Protein anti-cancer agent |
| 07/20/2000 | WO2000042429A2 In vitro model for gastrointestinal inflammation |
| 07/20/2000 | WO2000042213A1 A novel method for designing protein kinase inhibitors |
| 07/20/2000 | WO2000042208A1 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
| 07/20/2000 | WO2000042201A2 Human peptidases |
| 07/20/2000 | WO2000042186A1 NOVEL INTERFERON-$g(a) |
| 07/20/2000 | WO2000042181A1 Minor histocompatibility antigens and their use in diagnosis and treatment of tumors |
| 07/20/2000 | WO2000042179A2 Complex-forming proteins |
| 07/20/2000 | WO2000042172A2 Human homologues of proteins regulated by circadian rhythms |
| 07/20/2000 | WO2000042170A1 Novel lrsg protein and nucleic acid molecules and uses therefor |
| 07/20/2000 | WO2000042168A2 Bifidobacterium in the treatment of inflammatory disease |
| 07/20/2000 | WO2000042073A1 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 07/20/2000 | WO2000042072A2 Polypeptide variants with altered effector function |
| 07/20/2000 | WO2000042071A2 Compounds and methods to inhibit or augment an inflammatory response |
| 07/20/2000 | WO2000042064A1 Peptides for inhibiting hpv e6 proteins |
| 07/20/2000 | WO2000042063A2 Peptides for inhibiting hbv core proteins |
| 07/20/2000 | WO2000042062A1 Novel depsipeptide compound |
| 07/20/2000 | WO2000042042A2 High affinity inhibitors for target validation and uses thereof |
| 07/20/2000 | WO2000042040A1 Tricyclic inhibitors of poly(adp-ribose) polymerases |